Calaspargase pegol - Shire

Drug Profile

Calaspargase pegol - Shire

Alternative Names: Cal-PEG; EZN-2285; Oncaspar-IV; SC-PEG asparaginase; SC-PEG E. coli L-asparaginase; Scalasparagase pegol; SHP-663

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Children's Oncology Group; Dana-Farber Cancer Institute; Leadiant Biosciences; National Cancer Institute (USA); Shire
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 16 Apr 2018 Shire's agreement with Servier to sell its Oncology business is expected to close in the second or third quarter of 2018
  • 16 Apr 2018 Shire enters into a definitive agreement with Servier to sell its Oncology business
  • 28 Feb 2018 Preregistration for Precursor cell lymphoblastic leukaemia-lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top